HOME
>
臨床医学：外科
>
泌尿器科学
> ファーマナビゲーター　下部尿路機能障害編

ファーマナビゲーター　下部尿路機能障害編

出版社：	メディカルレビュー社
著者：	柿崎秀宏・吉田正貴／編
発行日：	2008-02-29
分野：	臨床医学：外科 > 泌尿器科学
ISBN：	9784779202216
シリーズ：	ファーマナビゲーター
電子書籍版：	2008-02-29 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

3,850 円(税込)

購入する

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

1,925 円(税込)

購入する

商品紹介

既に専門医の資格を取得した泌尿器科一般臨床医と専門医を取得すべく後期研修の課程にある新人泌尿器科医を主な読者として想定した解説書。

目次

ファーマナビゲーター　下部尿路機能障害編

―目次―

1. C型慢性肝炎・C型肝硬変症の患者さんの肝臓癌を防ぐために
2．現在使用されている肝庇護薬（抗炎症薬）の
　　　C型慢性肝疾患治療における一般的な評価
3．オーダーメイドな「抗炎症療法」のすすめ
4．炎症と肝発癌のメカニズム
　　　―初期C型肝硬変症の患者さんにおける発癌調査を含めて
5.「抗炎症療法」における薬剤の使い方
6．C型肝硬変症の患者さんへの「抗炎症療法」の成績
　　　―109例の患者さんの解析
7．10年間にわたる肝臓癌発癌の追跡結果
　　　―63例の患者さんの解析
8．C型慢性肝炎の患者さんへの「抗炎症療法」の成績
　　　―70例の患者さんの解析
9．各種の肝庇護薬における肝癌発生抑止のエビデンス
　　　―UDCA，SNMC，小柴胡湯
10．漢方製剤の有用性―特に十全大補湯について
11．C型慢性肝疾患に対するわれわれの「抗炎症療法」の成果
　　　―病気の抑制/肝癌発生抑止のエビデンス

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Chapter1 下部尿路機能障害の病態と診断

P.12 掲載の参考文献

1) Kakizaki H, Koyanagi T:Current view and status of the treatment of lower urinary tract symptoms and neurogenic lower urinary tract dysfunction. BJU Int 85:25-30, 2000

2) 本間之夫, 柿崎秀宏, 後藤百万ほか:排尿に関する疫学的研究. 日排尿機能会誌14:266-277, 2003

3) Rosier PF, de la Rosette JJ:Is there a correlation between prostate size and bladder-outlet obstruction? World J Urol 13:9-13, 1995

4) el Din KE, Kiemeney LA, de Wildt MJ et al:The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol 156:1020-1025, 1996

5) van Venrooij GE, Boon TA:The value of symptom score, quality of life score, maximal urinary flow rate, residual volume and prostate size for the diagnosis of obstructive benign prostatic hyperplasia:a urodynamic analysis. J Urol 155:2014-2018, 1996

6) Ameda K, Sullivan MP, Bae RJ, Yalla SV:Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol 162:142-146, 1999

7) 本間之夫, 塚本泰司, 安田耕作ほか:International Prostate Symptom Score と BPH Impact Index の日本語訳の言語的妥当性に関する研究. 日泌尿会誌 93:669-680, 2002

8) 泌尿器科領域の治療標準化に関する研究班編:EBMに基づく前立腺肥大症診療ガイドライン. 東京, じほう, 2001

P.27 掲載の参考文献

1) Abrams P, Cardozo L, Fall M et al:The standardisation of terminology of lower urinary tract function:report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167-178, 2002

2) 本間之夫, 西沢理, 山口脩:下部尿路機能に関する用語基準:国際禁制学会標準化部会報告. 日本排尿機能学会誌 14:278-289, 2003

3) Digesu GA, Khullar V, Cardozo L, Salvatore S:Overactive bladder symptoms:do we need urodynamics? Neurourol Urodyn 22:105-108, 2003

4) Flisser AJ, Walmsley K, Blaivas JG:Urodynamic classification of patients with symptoms of overactive bladder. J Urol 169:529-533, discussion 533-534, 2003

5) van Brummen HJ, Heintz AP, van der Vaart CH:The association between overactive bladder symptoms and objective parameters from bladder diary and filling cystometry. Neurourol Urodyn 23:38-42, 2004

6) 本間之夫, 柿崎秀宏, 後藤百万ほか:排尿に関する疫学的研究. 日本排尿機能学会誌 14:266-277, 2003

7) 本間之夫, 安藤高志, 吉田正貴ほか:尿失禁症状質問票の作成 (第一報):質問票の提示. 日本排尿機能学会誌 14:240-247, 2003

8) Jackson S, Donovan J, Brookes S et al:The Bristol Female Lower Urinary Tract Symptoms questionnaire:development and psychometric testing. Br J Urol 77:805-812, 1996

9) Donovan JL, Abrams P, Peters TJ et al:The ICS-'BPH' Study:the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 77:554-562, 1996

10) Barry MJ, Fowler FJ Jr, O'Leary MP et al:The American Urological Association symptom index for benign prostatic hyper-plasia. The Measurement Committee of the American Urological Association. J Urol 148:1549-1557, discussion 1564, 1992

11) O'Leary MP, Sant GR, Fowler FJ Jr et al:The interstitial cystitis symptom index and problem index. Urology 49:58-63, 1997

12) Bower WF, Moore KH, Adams RD:A novel clinical evaluation of childhood incontinence and urinary urgency. J Urol 166:2411-2415, 2001

13) Homma Y. Paick JS, Lee JG, Kawabe K;Japanese and Korean Tolterodine Study Group:Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder:a randomized, placebo-controlled trial. BJU Int 92:741-747, 2003

14) Herbison P, Hay-Smith J, Ellis G, Moore K:Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder:systematic review. BMJ 326:841-844, 2003

15) Freeman R, Hill S, Millard R et al:Reduced perception of urgencyin treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 102:605-611, 2003

16) Homma Y, Ando T, Yoshida M et al:Voiding and incontinence frequencies:variability of diary data and required diary length. Neurourol Urodyn 21:204-209, 2002

17) Schick E, Jolivet-Tremblay M, Dupont C et al:Frequency-volume chart:the minimum number of days required to obtain reliable results. Neurourol Urodyn 22:92-96, 2003

18) Brown JS, McNaughton KS, Wyman JF et al:Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 61:802-809, 2003

19) Ku JH, Jeong IG, Lim DJ et al:Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms:prospective assessment of patient compliance and burden. Neurourol Urodyn 23:331-335, 2004

20) 日本排尿機能学会過活動膀胱ガイドライン作成委員会編:過活動膀胱診療ガイドライン. ブラックウェルパブリッシング, 東京, 2005

21) 本間之夫, 吉田正貴, 小原健司ほか:過活動膀胱症状質問票 (overactive bladder symptom score:OABSS) の開発と妥当性の検討. 日本泌尿器科学会誌 96:182, 2005

22) 本間之夫, 松井研一, 山口脩:過活動膀胱の症例の下限基準. 日本排尿機能学会誌:109, 2004

23) Homma Y, Yoshida M, Seki N et al:Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 68:318-323, 2006

24) Sakakibara R, Fowler CJ, Hattori T:Voiding and MRI analysis ofthe brain. Int Urogynecol J Pelvic Floor Dysfunct 10:192-199, 1999

25) de Groat WC, Kawatani M, Hisamitsu T et al:Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 30:S71-S77, 1990

26) Yoshimura N:Bladder afferent pathway and spinal cord injury:possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neuorobiol 57:583-606, 1999

27) Speakman MJ, Brading AF, Gilpin CJ et al:Bladder outflow obstruction-a cause of denervation supersensitivity. J Urol 138:1461-1466, 1987

28) Seki N, Karim OM, Mostwin JL:The effect of experimental urethral obstruction and its reversal on changes in passive electrical properties of detrusor muscle. J Urol 148:1957-1961, 1992

29) Steers WD, Ciambotti J, Etzel B et al:Alterations in afferent pathways from the urinary bladder of the rat in response to partial urethral obstruction. J Comp Neurol 1310:401-410, 1991

30) Andersson KE, Hedlund P:Pharmacologic perspective on the physiology of the lower urinary tract. Urology 60:13-20, 2002

31) Araki I, Du S, Kamiyama M et al:Overexpression of epithelial sodium channel in the epithelium of human urinary bladder with outlet obstruction. Urology 64:1255-1260, 2004

32) Du S, Araki I, Mikami Y et al:Amiloride-sensitive ion channels in urinary bladder epithelium involved in mechanosensory transduction by modulating stretch-evoked adenosine triphosphate release. Urology 69:590-595, 2007

33) Chou EC, Flisser AJ, Panagopoulos G, Blaivas JG:Effective treatment for mixed urinary incontinence with a pubovaginal sling. J Urol 170:494-497, 2003

34) Jung SY, Fraser MO, Ozawa H et al:Urethral afferent nerve activity affects the micturition reflex;implication for the relationship between stress incontinence and detrusor instability. J Urol 162:204-212, 1999

P.43 掲載の参考文献

1) Sakakibara R, Fowler CJ, Hattori T:Voiding and MRI analysis of the brain. Int Urogynecol J Pelvic Floor Dysfunct 10:192-199, 1999

2) Yokoyama O, Ootsuka N, Komatsu K et al:Forebrain muscarinic control of micturition reflex in rats. IVeropharmacology 41:629-638, 2001

3) 慢性脊髄損傷における排尿障害の診療ガイドライン:過活動膀胱診療ガイドライン(日本排尿機能学会過活動膀胱診療ガイドライン作成委員会編). ブラックウェルパブリッシング, 東京, 2005, pp.57-65

4) 二分脊椎症に伴う下部尿路機能障害の診療ガイドライン:過活動膀胱診療ガイドライン(日本排尿機能学会過活動膀胱診療ガイドライン作成委員会編). ブラックウェルパブリッシング, 東京, 2005, pp.67-79

5) Krahn CG, Johnson HW:Cutaneous vesicostomy in the young child:indications and results. Urology 41:558-563, 1993

P.55 掲載の参考文献

1) 日本間質性膀胱炎研究会ガイドライン作成委員会:間質性膀胱炎診療ガイドライン. ブラックウェルパブリッシング, 東京, 2007

2) Parsons CL, Greenberger M, Gabal L et al:The role of urinary potassium in the pathogenesis and diagnosis of interstitial cystitis. J Urol 159:1862-1866, discussion 1866-1867, 1998

3) Anderstrom CR, Fall M, Johansson SL:Scanning electron microscopic findings in interstitial cystitis. Br J Urol 63:270-275, 1989

4) Keay S, Seillier-Moiseiwitsch F, Zhang CO et al:Changes in human bladder epithelial cell gene expression associated with interstitial cystitis or antiproliferative factor treatment. Physiol Genomics 14:107-115, 2003

5) Zeng Y, Wu XX, Homma Y et al:Uroplakin III-Delta4 Messenger RNA as a Promising Marker to Identify Nonulcerative Interstitial Cystitis. J Urol 178:1322-1327, 2007

6) Ochs RL, Stein TW Jr, Peebles CL et al:Autoantibodies in interstitial cystitis. J Urol 151:587-592, 1994

7) Theoharides TC, Kempuraj D, Sant GR:Mast cell involvement in interstitial cystitis:a review of human and experimental evidence. Urology 57:47-55, 2001

8) Ueda T, Tamaki M, Ogawa O, Yoshimura N:Over expression of plateletderived endothelial cell growth factor/thymidine phosphorylase in patients with interstitial cystitis and bladder carcinoma. J Urol 167:347-351, 2002

9) Hanno PM, Landis JR, Matthews-Cook Y et al:The diagnosis of interstitial cystitis revisited:lessons learned from the National Institutes of Health Interstitial Cystitis Database study. J Urol 161:553-557, 1999

10) 本間之夫:過知覚膀胱 (過敏性膀胱). Medical Practice 22:1272-1274, 2005

P.66 掲載の参考文献

1) Abrams P, Cardozo L, Fall M et al:The standardisation of terminology of lower urinary tract function:report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21:167-178, 2002

2) DeLancey JO:Structural support of the urethra as it relates to stress urinary incontinence:the hammock hypothesis. Anz J Obstet Gynecol 170:1713-1723, 1994

3) Raz S, Little NA, Juma S:Female urology. Campbell's urology (Walsh PC et al eds.). WB Saunders, Philadelphia, 1982, pp.2782-2828

4) Blaivas JG, Olsson CA:Stress incontinence:classification and surgical approach. J Urol 139:727-731, 1988

5) McGuire EJ, Lytton B, Kohorn EI, Pepe V:The value of urodynamic testing in stress urinary incontinence. J Urol 124:256-258, 1980

6) 山口脩, 嘉村康邦, 宍戸啓一監:女性の腹圧性尿失禁(Stress Urinary Incontinence; SUI). 図説下部尿路機能障害. メディカルレビュー社, 大阪, 2004, pp.53-63

P.77 掲載の参考文献

1) Krieger JN, Nyberg L Jr, Nickel JC:NIH consensus definition and classification of prostatitis. JAMA:282:236-237, 1999

2) Nickel JC:Inflammatory Conditions of the Male Genitourinary Tract:Prostatitis and Related Conditions. Orchitis, and Epididymitis. Campbell and Walsh Urology 9th ed(Wein AJ et al eds.). Saunders, Philadelphia, 2007, pp.304-329

3) Nickel JC, Alexander RB, Schaeffer AJ et al:Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syn-drome compared to asymptomatic controls. J Urol 170:818-822, 2003

4) Litwin MS, McNaughton-Collins M, Fowler FJ Jr et al:The National Institute of Health chronic prostatitis symptom index:development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol 162:369-375, 1999

5) Kunishima Y, Matsukawa M, Takahashi S et al:National Institute of Health Chronic prostatitis Symptom Index for Japanese men. Urology 60:74-77, 2002

6) 国島康晴:前立腺炎症状スコア (NIH-CPSI) 日本語版 (案). 泌尿器科感染症外来 (塚本泰司編). メジカルビュー社, 東京, 2003, pp.126-127

7) Pontari MA, Ruggieri MR:Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol 172:839-845, 2004

8) Parsons CL:The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 69:9-16, 2007

9) Forrest JB, Nickel JC, Moldwin RM:Chronic prostatitis/chronic pelvic pain syndrome and male interstitial cystitis:enigmas and opportunities. Urology 69:60-63, 2007

10) Schaeffer AJ, Knauss JS, Landis JR et al:Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis:the National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 168:1048-1053, 2002

11) Nickel JC, Roehrborn CG, O'leary MP et al:Examination of the relationship between symptoms of prostatitis and histological inflammation:baseline data from the REDUCE chemoprevention trial. J Urol 178:896-901, 2007

12) John H, Barghorn A, Funke G et al:Noninflammatory chronic pelvic pain syndrome:immunological study in blood, ejaculate and prostate tissue. Eur Urol 39:72-78, 2001

13) Orhan I, Onur R, Ilhan N, Ardicoglu A:Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome. Int J Urol 8:495-499, 2001

14) Alexander RB, Ponniah S, Hasday J, Hebel JR:Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome. Urology 52:744-749, 1998

15) Nadler RB, Koch AE, Calhoun EA et al:IL-1β and TNF-α in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol 164:214-218, 2000

16) Miller LJ, Fischer KA, Goralnick SJ et al:Interleukin-10 levels in seminal plasma:implications for chronic prostatitis-chronic pelvic pain syndrome. J Urol 167:753-756, 2002

17) Jang TL, Schaeffer AJ:The role of cytokines in prostatitis. World J Urol 21:95-99, 2003

18) Kohn IJ, Kaplan SA:The role of urodynamics in evaluating patients with chronic prostatitis. Textbook of prostatitis(Nickel JC ed.). ISIS Medical Media, Oxford, 1999, pp.227-232

19) Ghobish A:Voiding dysfunction associated with"chronic bacterialprostatitis". Eur Urol 42:159-162, 2002

20) Hruz P, Danuser H, Studer UE, Hochreiter WW:Non-inflammatory chronic pelvic pain syndrome can be caused by bladder neckhypertrophy. Eur Urol 44:106-110, 2003

21) Nakai H, Yamanashi T, Yasuda K et al:Correlation between lowerurinary tract symptoms and urethral function in benign prostatichyperplasia. Neurourol Urodyn 23:618-622, 2004

22) Toh KL, Ng CK:Urodynamic studies in the evaluation of youngmen presenting with lower urinary tract symptoms. Int J Urol 13:520-523, 2006

23) Schneider H, Wilbrandt K, Ludwig M et al:Prostate-related pain in patients with chronic prostatitis/chronic pelvic pain syndrome. BJU Int 95:238-243, 2005

24) Mehik A, Hellstrom P, Nickel JC et al:The chronic prostatitischronic pelvic pain syndrome can be characterized by prostatic tissue pressure measurements. J Urol 167:137-140, 2002

25) Yang CC, Lee JC, Kromm BG et al:Pain sensitization in malechronic pelvic pain syndrome:why are symptoms so difficult to treat? J Urol 170:823-827, 2003

26) Hetrick DC, Ciol MA, Rothman I et al:Musculoskeletal dysfunctionin men with chronic pelvic pain syndrome type III:a case-control study. J Urol 170:828-831, 2003

27) Mishra VC, Browne J, Emberton M:Role of α-blockers in type III prostatitis:a systematic review of the literature. J Urol 177:25-30, 2007

28) Dimitrakov JD, Kaplan SA, Kroenke K et al:Management of chronic prostatitis/chronic pelvic pain syndrome:an evidencebased approach. Urology 67:881-888, 2006

29) Nickel JC Downey J, Ardern D et al:Failure of a monotherapystrategy for difficult chronic prostatitis/chronic pelvic pain syndrome. J Urol 172:551-554, 2004

30) Nickel JC:The three As of chronic prostatitis therapy:antibiotics, α-blockers and anti-inflammatories. What is the evidence? BJU Int 94:1230-1233, 2004

31) Tugcu V, Tasci AI, Fazlioglu A et al:Aplcabo-controlled comparison of the efficiency of triple-and monotherapy in category III Bchronic pelvic pain syndrome (CPPS) . Eur Urol 51:1113-1118, 2007

P.97 掲載の参考文献

1) Neveus T, von Gontard A, Hoebeke P et al:The standardization of terminology of lower urinary tract function in children and adolescents:report from the Standardisation Committee of the International Children's Continence Society. J Urol 176:314-324, 2006

2) Hjalmas K, Arnold T, Bower W et al:Nocturnal enuresis:an international evidence based management strategy. J Urol 171:2545-2561, 2004

3) Holmdahl G, Hanson E, Hanson M e al:Four-hourvoiding observation in healthy infants. J Urol 156:1809-1812, 1996

4) Persson de Geeter C:Overactive bladder syndrome in children. Urologe A 43:807-812, 2004

Chapter 2 下部尿路機能障害治療薬の薬理と作用メカニズム

P.114 掲載の参考文献

1) 大島伸一, 平尾佳彦, 長谷川友紀:前立腺肥大症の診療ガイドライン. 日本医事新報 4039:1-11, 2001

2) Cavalli A, Lattion AL, Hummler E et al:Decreased blood pressure response in mice deficient of the α1b-adernergic receptor. Proc Natl Acad Sci USA 94:11589-11594, 1997

3) Schwinn DA:Novel role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 86:11-22, 2000

4) Nasu K, Moriyama N, Kawabe K et al:Quantification and distribution of α1-adrenoceptor subtype mRNAs in human prostate:comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 119:797-803, 1996

5) Hampel C, Dolber PC, Smith MP et al:Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol 167:1513-1521, 2002

6) Smith MS, Schambra UB, Wilson KH et al:α1-adrenergic receptors in human spinal cord:specific localized expression of mRNA encording α1-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res 63:254-261, 1999

7) Ishihama H, Momota Y, Yanase H et al:Activation of α1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol 175:358-364, 2006

8) Djavan B, Marberger M:Ameta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36:1-13, 1999

9) Lepor H, Jones K, Williford W:The mechanism of adverse events associated with terazosin:an analysis of the Veterans Affairs cooperative study. J Urol 163:1134-1137, 2000

10) Kawabe K, Yoshida M, Homma Y;Silodosin Clinical Study Group:Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia:results of phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019-1024, 2006

11) Chen Q, Takahashi S, Zhong S et al:Function of the lower urinary tract in mice lacking α1D-adorenoceptor. J Urol 174:370-374, 2005

12) Persson K, Pandita RK, Spitsbergen JM et al:Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 275:R1366-R1373, 1998

13) Sugaya K, Nishijima S, Miyazono M et al:Effects of intrathecal injection of tamsulosin and naftopidil, α-1A and α-1D adrenergicreceptor antagonists, on bladder activity in rats. Neurosci Lett 328:74-76, 2002

14) Nomiya M, Yamaguchi O:A quantitative analysis of mRNA expression of α1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170:649-653, 2003

15) Yokoyama O, Nagano K, Kawaguchi K et al:The influence of prostatic urethral anesthesia in overactive detrusor in patients with benign prostatic hyperplasia. J urol 151:1554-1556, 1994

16) Yokoyama O, Yusup A, Oyama N et al:Improvement in bladder storage function by tamsulosin depends on suppression of C-fiberurethral afferent activity in rats. J Urol 177:771-775, 2007

17) Levin RM, Leggett RE, Eagen G, Das AK:Effect of doxazosin on bladder function after partial outlet obstruction in rats. J Urol 165:206, 2001

18) Kyprianou N:Doxazosin and terazosin suppress prostate growth byinducing apoptosis:clinical significance. J Urol 169:1520-1525, 2003

19) Djavan B, Marberger M:Ameta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 136:1-13, 1999

20) Witjes WP, Rosier PF, Caris CT et al:Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction:a stratified analysis. Urology 49:197-206, 1997

21) Athanasopoulos A, Gyftopoulos K, Giannitsas K et al:Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction:a prospective, randomized, controlled study. J Urol 169:2253-2256, 2003

22) Lee JY, Kim HW, Lee SJ et al:Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817-820, 2004

23) Lee KS, Choo MS, Kim DY et al:Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction:a prospective, randomized, controlled multicenter study. J Urol 174:1334-1338, 2005

24) Kaplan SA, Roehrborn CG, Rovner ES et al:Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder:a randomized controlled trial. JAMA 296:2319-2328, 2006

25) 志田圭三, 小柳知彦, 川倉宏一ほか:二重盲検法におけるアリルエストレノールの前立腺肥大症に対する臨床効果. 泌尿紀要 32:625-648, 1986

26) 阿曽佳郎, 本間之夫, 熊本悦明ほか:5α-Reductase阻害剤MK-906の前立腺肥大症患者に対する臨床第III相試験-酢酸クロルマジノン徐放錠を対照薬とする二重盲検群間比較試験-. 泌尿器外科 8:237-256, 1995

27) McConnell JD, Roehrborn CG, Bautista OM:The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387-2398, 2003

28) Yoshida H, Haraguchi C, Ogawa Y et al:Clinical effects of chlormadinone acetate (Prostal) on patients with prostatic hypertrophy with reference to estimation of size and weight of prostate by means of transrectal ultrasonography. Hinyokika Kiyo 29:1419-1426, 1983

29) MacDonald R, Ishani A, Rutks I, Wilt TJ:A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int 85:836-841, 2000

30) Yamagichi O, Shiraiwa Y, Kobayashi M et al:Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. Urol Int 45:40-46, 1990

31) 吉田正貴, 稲留彰人, 大谷将之ほか:LUTSの治療-主に薬物療法について. 排尿障害プラクティス 11:307-314, 2003

P.129 掲載の参考文献

1) Andersson K-E, Appell R, Cardozo L et al:Pharmacological treatment of urinary incontinence. Incontinence. Volume 2 International Consultation on Incontinence(Abrams P et al eds.). Health Publication, France, 2005, PP.811-854

2) 日本排尿機能学会過活動膀胱診療ガイドライン作成委員会編:過活動膀胱診療ガイドライン. ブラックウェルパブリッシング, 東京, 2005

3) Lee JY, Kim HW, Lee SJ et al:Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817-820, 2004

4) Yokoyama O, Nagano K, Kawaguchi K et al:The influence of prostatic urethral anesthesia in overactive detrusor in patients with benign prostatic hyperplasia. J Urol 151:1554-1556, 1994

5) de Groat WC, Kawatani M, Hisamitsu T et al:Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 30:S71-S77, 1990

6) Dorschner W, Stolzenburg JU, Griebenow R et al:Efficacy and cardiac safety of propiverine in elderly patients-a double-blind, placebo-controlled clinical study. Eur Urol 37:702-708, 2000

7) Madersbacher H, Halaska M, Voigt R et al:A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646-651, 1999

8) Wehnert J, Sage S:Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle. Z Urol Nephrol 82:259-263, 1989

Chapter 3 下部尿路機能障害の薬物治療のEBM

P.134 掲載の参考文献

1) アステラス製薬株式会社育薬研究所市販後調査センター:前立腺肥大症に伴う排尿障害に対するハルナール(R)の有効性・安全性に関する大規模調査. 新薬と臨牀 55:403-426, 2006

2) Lee E, Lee C:Clinical comparison of selective and non-selective α1A adrenoreceptor antagonists in benign prostatic hyperplasia:studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 80:606-611 1997

3) Kawabe K, Homma Y, Kubota K, Sozu T;THE TAMSULOSIN LONG-TEAM STUDY GROUP*:How frequent are invasive therapies required in patients receiving tamsulosin for benign prostatic hyperplasia? A retrospective long-term study. Int J Urol 13:127-1312006

4) Nishino Y, Masue T, Miwa K et al:Comparison of two α1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia:a randomized crossover study. BJU Int 97:747-751, 2006

5) 瀬川直樹, 濱田修史, 上原博史ほか:前立腺肥大症治療薬 (α1ブロッカー) における射精障害の検討. 日本性機能学会誌 22:176-177, 2007

6) Kawabe K, Yoshida M, Homma Y;Silodosin Clinical Study Group:Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia:results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019-1024, 2006

7) Lee KS, Choo MS, Kim DY et al:Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overacitive bladder and coexisting benign prostatic obstruction:a prospective, randomized, controlled multicenter study. J Urol 174:1334-1338, 2005

P.140 掲載の参考文献

1) 吉田正貴, 井川靖彦, 小原健司, 関成人:過活動膀胱診療ガイドライン (日本排尿機能学会過活動膀胱診療ガイドライン作成委員会編). ブラックウェルパブリッシング, 東京, 2005, pp.33-45

2) Madersbacher H, Halaska M, Voigt R et al:Aplacebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 84:646-651, 1999

3) Homma Y, Paick JS, Lee JG, Kawabe K:Japanese and Korean Tolterodine Study Group:Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder:a randomized, placebo-controlled trial. BJU Int 92:741-747, 2003

4) Yamaguchi O, Marui E, Kakizaki H et al:Randomized, doubleblind, Placebo-and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int 100:579-587, 2007

5) Chapple CR, Martinez-Garcia R, Selvaggi L et al:Acomparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome:results of the STAR trial. Eur Urol 48:464-470, 2005

Chapter 4 下部尿路機能障害の病態に応じた治療の実際

P.152 掲載の参考文献

1) Djavan B, Marberger M:A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36:1-13, 1999

2) Martorana G, Giberti C, Di Silverio F et al:Effects of short-term treatment with the α1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol 32:47-53, 1997

3) Ozbey I, Aksoy Y, Polat O et al:Effects of doxazosin in men with benign prostatic hyperplasia:urodynamic assessment. Jnt Urol Nephrol 31:471-479, 1999

4) Ichioka K, Ohara H, Terada N et al:Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int J Urol 11:870-875, 2004

5) 河邉香月, 吉田正貴, 荒川創一, 竹内秀雄:シロドシン臨床試験グループ:新規α1A選択的アドレナリン受容体遮断薬シロドシンの前立腺肥大症に伴う下部尿路機能障害に対する長期投与時の評価-第III相長期投与試験-. 泌尿器外科 19:153-164, 2006

6) Michel MC, Mehlburger L, Bressel HU et al:Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms:does comorbidity alter tolerability? J Urol 160:784-791, 1998

7) Lepor H, Williford WO, Barry MJ et al:The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 335:533-539, 1996

8) Elhilari MM, Ramsey EW, Barkin J et al:A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 47:335-342, 1996

9) Lepor H:Long-term evaluation of tamsulosin in benign prostatic hyperplasia:placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 51:901-906, 1998

10) Kawabe K, Yoshida M, Homma Y:Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia:results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019-1024, 2006

11) Abrams P, Kaplan S, De Koning Gans HJ, Millard R:Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 1751999-1004, 2006

12) McConnell JD, Roehrborn CG, Bautista OM et al:The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387-2398, 2003

13) Athanasopoulos A, Gyftopoulos K, Giannitsas K et al:Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction:aprospective, randomized, controlled study. J Urol 169:2253-2256, 2003

14) Lee KS, Choo MS, Kim DY et al:Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction:a prospective, randomized, controlled multicenter study. J Urol 174:1334-1338, 2005

15) Lee JY, Kim HW, Lee SJ et al:Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817-820, 2004

16) Kaplan SA, Roehrborn CG, Rovner ES et al:Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder:a randomized controlled trial JAMA 296:2319-2328, 2006

17) 吉田正貴, 稲留彰人, 大谷将之ほか:LUTSの治療-主に薬物療法について. 排尿障害プラクティス 11:307-314, 2003

P.165 掲載の参考文献

1) Abrams P, Cardozo L, Fall M et al:The standardisation of terminology in lower urinary tract function:report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167-178, 2002

2) 安田耕作, 井川靖彦, 山西友典, 北原聡史:排尿障害を起こす疾患と薬物療法. 排尿障害の薬物治療. 三輪書店, 東京, 2000, pp.136-172

3) 日本排尿機能学会過活動膀胱診療ガイドライン作成委員会編:過活動膀胱診療ガイドライン. ブラックウェルパブリッシング, 東京, 2005

4) Rackley R, Weiss JP, Rovner ES et al:Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 67:731-736, 2006

5) Reynard JM, Cannon A, Yang Q, Abrams P:A novel therapy for nocturnal polyuria:a double-blind randomized trial of frusemide against placebo. Br J Urol 81:215-218, 1998

6) Kaplan SA, Roehrborn CG, Rovner ES et al:Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder:a randomized controlled trial. JAMA 296:2319-2328, 2006

7) Yasuda K, Yamanishi T, Kawabe K et al:The effect of urapidil on neurogenic bladder:a placebo controlled double-blind study. J Urol 156:1125-1130, 1996

P.174 掲載の参考文献

1) 本間之夫, 柿崎秀宏, 後藤百万ほか:排尿に関する疫学的研究. 日本排尿機能学会誌 14:266-277, 2003

2) Hunskaar S, Burgio K, Diokno A et al:Epidemiology and natural history of urinary incontinence in women. Urology 62:16-23, 2003

3) 島崎淳, 安田耕作, 永嶌薫ほか:頻尿・尿失禁に対するクレンブテロールの臨床薬効評価. 西日泌尿 51:1745-1758, 1989

4) 島崎淳, 安田耕作, 今林健一ほか:腹圧性尿失禁に対するクレンブテロールの臨床効果-用量設定試験. 泌尿器外科 5:933-945, 1992

5) Dmochowski RR, Miklos JR, Norton PA et al:Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170:1259-1263, 2003

6) Duckett JR, Vella M, Kavalakuntla G, Basu M:Tolerability and efficacy of duloxetine in a nontrial situation. BJOG 114:543-547, 2007

7) Gilja I, Radej M, Kovacic M, Parazajder J:Conservative treatment of female stress incontinence with imipramine. J Urol 132:909-911, 1984

8) 横山英二, 石田裕則, 真下節夫ほか:女性の腹圧性尿失禁に対する塩酸ミドドリンの有用性に関する検討. 泌尿器外科 5:1273-1279, 1992

9) 鈴木泰宏, 石郷岡学, 橋本透ほか:腹圧性尿失禁に対するメチル酸アメジニウムの効果. 臨泌 51:733-738, 1997

10) Alhasso A, Glazener CM, Pickard R, N'dow J:Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 20:CD001842, 2005

11) Hormone replacement therapy aggravates postmenopausal urinary incontinence. Prescrire Int 15:137-138, 2006

12) Hendrix SL, Cochrane BB, Nygaard IE et al:Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935-948, 2005

13) Du Beau CE:Estrogen treatment for urinary incontinence:never, now, or in the future? JAMA 293:998-1001, 2005

P.183 掲載の参考文献

1) Simmons JL, Bunce PL:On the use of antihistamine in the treatment of interstitial cystitis. Am Surg 24:664-667, 1958

2) Simmons JL:Interstitial cystitis:An explanation for beneficial effect of an antihistamine. J Urol 85:149-155, 1961

3) Minogiannis P, El-Mansoury M, Betances JA et al:Hydroxyzine inhibits neurogenic bladder mast cell activation. Int J Immunophar macol 20:553-563, 1998

4) Theoharides TC:Hydroxyzine for interstitial cystitis. J Allergy Clin Immunol 91:686-687, 1993

5) Theoharides TC:Hydroxyzine in the treatment of interstitial cystitis. Urol Clin North Am 21:113-119, 1994

6) Theoharides TC, Sant GR:Hydroxyzine therapy for interstitial cystitis. Urology 49:108-110, 1997

7) Sant GR, Propert KJ, Hanno PM et al:Apilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 170:810-815, 2003

8) Hanno PM, Wein AJ:Medical treatment of interstitial cystitis (other than Rimso-50/Elmiron). Urology 29:22-26, 1987

9) Rovner E, Propert KJ, Brensinger C et al:Treatments used in women with interstitial cystitis:the Interstitial cystitis data base (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology 56:940-945, 2000

10) Hanno PM, Wein AJ:Conservative therapy of interstitial cystitis. Semin Urol 9:143-147, 1991

11) Pranikoff K, Constantino G:The use of amitriptyline in patients with urinary frequency and pain. Urology 51:179-181, 1998

12) Kirkemo AK, Miles BJ, Peters JM:Use of amitriptyline in the treatment of interstitial cystitis. J Urol 143:279A, 1990

13) van Ophoven A, Pokupic S, Heinecke A, Hertle L:Aprospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment Of interstitial cystitis. Jr Urol 172:533-536, 2004

14) Ueda T, Tamaki M, Ogawa O et al:Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. J Urol 164:1917-1920, 2000

15) 長岡深雪, 玉置淳, 後藤慎一ほか:シェーグレン症候群に間質性膀胱炎と間質性肺炎を合併し, トシル酸スプラタストおよびプレドニゾロンにて改善した1例. アレルギー 52:450-453, 2003

16) Seshadri P, Emerson L, Morales A:Cimetidine in the treatment of interstitial cystitis. Urology 44:614-616, 1994

17) Lewi H:Cimetidine in treatment of interstitial cystitis. Urology 45:1088, 1995

18) Lewi H:Medical therapy in interstitial cystitis:the essex experience. Urology 57:120, 2001

19) Thilagarajah R, Witherow RO, Walker MM:Oral cimetidine gives effective symptom relief in painful bladder disease:aprospective, randomized, double-blind placebo-controlled trial. BJU Int 87:207-212, 2001

20) Dasgupta P, Sharma SD, Womack C et al:Cimetidine in painfulbladder syndrome:a histopathological study. BJU Int 88:183-186, 2001

21) Badenoch AW:Chronic interstitial cystitis. Br J Urol 43:718-721, 1971

22) Peeker R, Haghsheno MA, Holmang S, Fall M:Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis:a prospective, randomized double-blind study. J Urol 164:1912-1916, 2000

23) Perez-Marrero R, Emerson LE, Feltis JT:A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 140:36-39, 1988

24) Sant GR:Intravesical 50% dimethyl sulfoxide(Rimso-50)in treatment of interstitial cystitis. Urology 29:17-21, 1987

25) Kuo HC:Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. Formos Med Assoc 10:309-314, 2001

26) Parsons CL, Housley T, Schmidt JD, Lebow D:Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73:504-507, 1994

27) Parsons CL:Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 65:45-48, 2005

P.190 掲載の参考文献

1) Krieger JN, Nyberg L Jr, Nickel JC:NIH consensus definition and classification of prostatitis. JAMA 282:236-237, 1999

2) 国島康晴:前立腺炎, 泌尿器科感染症外来 (塚本泰司編). メジカルビュー社, 東京, 2003, pp.62-81

3) 日本泌尿器科学会尿路感染症臨床試験ガイドライン作成委員会編:前立腺炎. 尿路感染症臨床試験ガイドライン. 金原出版, 東京, 1998, pp35-40

4) Litwin MS, McNaughton-Collins M, Fowler FJ Jr et al:The National Institutes of Health chronic prostatitis symptom index:development and validation of a new outcome measure. J Urol 162:369-375, 1999

5) PROSTATITIS AND CHRONIC PELVIC PAIN SYNDROME:Guidelines on The Management of Urinary and Male Genital Tract Infections. European Association of Urology Guidelines 2007 (European Association of Urology ed.). 2007, pp. 89-98

6) Krieger JN, Riley DE, Roberts MC, Berger RE:Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol 34:3120-3128, 1996

7) Takeyama K, Mitsuzawa H, Nishitani C et al:The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3. Antimicrob Agents Chemother 51:162-168, 2007

8) Cheah PY, Liong ML, Yuen KH et al:Terazosin therapy for chronicprostatitis/chronic pelvic pain syndrome:a randomized, placebocontrolled trial. J Urol 169:592-596, 2003

9) Alexander RB, Propert KJ, Schaeffer AJ et al:Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome:a randomized, double-blind trial. Ann Intern Med 141:581-589, 2004

Chapter5 診療に関するQ&A

P.201 掲載の参考文献

1) 伊藤一人, 山本巧, 大井勝ほか:前立腺集団検診受診者における国際前立腺症状スコアー(I-PSS)の傾向とQOL indexとの関係. 泌尿器外科 14:868-871, 2001

2) 福多史昌, 舛森直哉, 田中吉則ほか:下部尿路症状を主訴とする受診症例における前立腺癌発見率. 臨床泌尿器科 59:133-138, 2005

3) Lepor H, Owens RS, Rogenes V, Kuhn E:Detection of prostate cancer in males with prostatism. Prostate 25:132-140, 1994

4) Ito K, Yamamoto T, Kubota Y et al:Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 56:278-282, 2000

5) Ito K, Ohi M, Yamamoto T et al:The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4. 1-10. O ng/mL. Cancer 95:2112-2119, 2002

6) Catalona WJ, Smith DS, Wolfert RL et al:Evaluation of percentage of free serum prostate-specific antigen to improve specificity of Prostate cancer screening. JAMA 274:1214-1220, 1995

7) Prestigiacomo AF, Lilja H, Pettersson K et al:A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates:the best case scenario. J Urol 156:350-354, 1996

8) Partin AW, Catalona WJ, Southwick PC et al:Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection:influence of total PSA, prostate volume, and age. Urology 48:55-61, 1996

9) Kikuchi E, Nakashima J, Ishibashi M et al:Prostate specific antigen adjusted for transition zone volume:the most powerful method for detecting prostate carcinoma. Cancer 89:842-849, 2000

10)大井勝, 山本巧, 伊藤一人ほか:前立腺がん集団検診における年齢階層別PSA基準値の導入-80歳以上のPSA基準値引き上げに関する検討-. 日本がん検診・診断学会誌 10:123-125, 2003

11) Yamamoto T, Ito K, Ohi M et al:Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. Urology 58:994-998, 2001

12) Schroder FH, van der Cruijsen-Koeter I, de Koning HJ et al:Prostate cancer detection at low prostate specific antigen. J Urol 163:806-812, 2000

13) Makinen T, Tammela TL, Hakama M et al:Prostate cancer screening within a prostate specific antigen range of 3 to 3. 9 ng. /ml.:a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J Urol 166:1339-1342, 2001

14) Bozeman CB, Carver BS, Caldito G et al:Prostate cancer in patients with an abnormal digital rectal examination and serum prostatespecific antigen less than 4.O ng./mL. Urology 66:803-807, 2005

15) Fowler JE JR, Bigler SA, Farabaugh PB, Wilson SS:Prostatecancer detection in Black and White men with abnormal digitalrectal examination and prostate specific antigen less then 4 ng./ml. J Urol 164:1961-1963, 2000

16) Catalona WJ, Partin AW, Finlay JA et al:Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer:an alternative model. Urology 54:220-224, 1999

17) Thompson IM, Pauler DK, Goodman PJ et al:Prevalence of prostate cancer among men with a prostate-specific antigen level<or=4.0 ng per milliliter. N Engl J Med 350:2239-2246, 2004

18) Ohi M, Ito K, Suzuki K et al:Diagnostic significance of PSA density adjusted by transition zone volume in males with PSA levels between 2 and 4 ng/ml. Eur Urol 45:92-96, 2004

19) Djavan B, Zlotta A, Kratzik C et al:PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.O ng/mL. Urology 54:517-522, 1999

20) Ito K, Ichinose Y, Kubota Y et al:Clinicopathological features of prostate cancer detected by transrectal ultrasonography-guided systematic six-sextant biopsy. Int J Urol 4:474-479, 1997

21) Catalona WJ, Richie JP, Ahmann FR et al:Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer:results of a multicenter clinical trial of 6,630 men. J Urol 151:1283-1290, 1994

22) Babaian RJ, Toi A, Kamoi K et al:A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 163:152-157, 2000

23) Hammerer P, Huland H:Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol 151:99-102, 1994

24) Brawer MK, Chetner MP, Beatie J et al:Screening for prostate carcinoma with prostate specific antigen. J Urol 147:841-845, 1992

25) Keetch DW, Catalona WJ, Smith DS:Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151:1571-1574, 1994

26) Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL:Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 163:158-162, 2000

27) Eskew LA, Bare RL, McCullough DL:Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 157:199-203, 1997

28) Vashi AR, Wojno KJ, Gillespie B, Oesterling JE:A model for the number of cores per prostate biopsy based on patient age and prostate gland volume. J Urol 159:920-924, 1998

29) 伊藤一人, 山本巧, 大井勝ほか:PSA 4.1～10 ng/mlにおける前立腺生検方法の検討. 泌尿器外科 15:934-937, 2002

30) Ito K, Yamamoto T, Ohi M et al:Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer. Int J Cancer 109:455-460, 2004

31) Ito K, Yamamoto T, Ohi M et al:Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less. Prostate 57:8-13, 2003

32) Ito K, Yamamoto T, Suzuki K et al:The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.O ng/ml or less. J Urol 171:656-660, 2004

33) Guess HA, Gormley GJ, Stoner E, Oesterling JE:The effect of finasteride on prostate specific antigen:review of available data. J Urol 155:3-9, 1996

34) Oesterling JE, Roy J, Agha A et al:Biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer:effects of finasteride. The Finasteride PSA Study Group. Urology 50:13-18, 1997

P.208 掲載の参考文献

1) Rudner XL, Berkowitz DE, Booth JV et al:Subtype specific regulation of human vascular α1-adrenergic receptors by vessel bed and age. Circulation 100:2336-2343, 1999

2) Hajjar I:Postural blood pressure changes and orthostatic hypotension in the elderly patient:impact of antihypertensive medications. Drugs Aging 22:55-68, 2005

3) Rose KM, Tyroler HA, Nardo CJ et al:Orthostatic hypotension and the incidence of coronary heart disease:the Atherosclerosis Risk in Communities study. Am J Hypertens 13:571-578, 2000

4) 今鷹耕二:主な降圧薬の特徴と使用法交感神経遮断薬 (α遮断薬, β遮断薬) の特徴と使用法. 診断と治療 94:402-405, 2006

5) 梅村敏:α遮断薬. 血圧 13:1367-1375, 2006

6) Holtzman JL, Kaihlanen PM, Rider JA et al:Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. Arch Intern Med 148:539-543, 1988

7) Stokes GS, Gain JM, Mahony JF et al:Long-term use of prazosin in combination or alone for treating hypertension. Med J Aust 20:13-16, 1977

8) Pool JL:Combination antihypertensive therapy with terazosin and other antihypertensive agents:results of clinical trials. Am Heart J 122:926-931, 1991

9) Elliott HL, Meredith PA, Campbell L, Reid JL:The combination of prazosin and verapamil in the treatment of essential hypertension. Clin Pharmacol Ther 43:554-560, 1988

10) Puddey IB, Beilin LJ, Vandongen R et al:Differential effects of sulindac and indomethacin on blood pressure in treated essential hypertensive subjects. Clin Sci (Lond) 69:327-336, 1985

11) Jackson G, Montorsi P, Cheitlin MD:Cardiovascular safety of sildenafil citrate (Viagra):an updated perspective. Urology 68:47-60, 2006

P.212 掲載の参考文献

1) Chang DF, Campbell JR:Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 31:664-673, 2005

2) Oshika T, Ohashi Y, Inamura M et al:Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical α1-adrenoceptor antagonist. Ani J Ophthalmol 143:150-151, 2007

3) Hiraizumi-Hiraoka Y, Tanaka T, Yamamoto H et al:Identification of α1L adrenoceptor in rabbit ear artery. J Pharmacol Exp Ther 310:995-1002, 2004

P.217 掲載の参考文献

1) AUA Practice Guidelines Committee:AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1:Diagnosis and treatment recommendations. J Urol 170:530-547, 2003

2) 古屋亮兒, 久末伸一, 古屋聖兒ほか:前立腺肥大症症例に対するα1ブロッカーによる射精障害の検討-塩酸タムスロシンとナフトピジルの比較-. 泌尿紀要 51:763-766, 2005

3) Hisasue S, Furuya R, Itoh N et al:Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol 13:1311-1316, 2006

4) Kawabe K, Yoshida M, Homma Y;Silodosin Clinical Study Group:Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia:results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019-1024, 2006

5) 小林皇, 舛森直哉, 伊藤直樹, 塚本泰司:前立腺肥大症治療薬の性機能への影響-選択的α1A遮断薬による射精障害の検討. 日泌尿会誌 98:268, 2007

6) Schulman CC:Lower urinary tract symptoms/benign prostatic hyperplasia:minimizing morbidity caused by treatment. Urology 62:24-33, 2003

7) Frankel SJ, Donovan JL, Peters TI et al:Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 51:677-685, 1998

8) Goktas S, Kibar Y, Kilic S et al:Recovery of abnormal ejaculation by intermittent tamsulosin treatment. J Urol 175:650-653, 2006

P.221 掲載の参考文献

1) McConnell JD, Bruskewitz R, Walsh P et al:The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557-563, 1998

2) Roehrborn CG, Boyle P, Nickel JC et al:Efficacy and safety of a dual inhibitor of 5-alpha-reductase type l and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434-441, 2002

3) Rosen RC, Giuliano F, Carson CC:Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) . Eur Urol 47:824-837, 2005

4) Lowe FC:Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia:sexual function. BJU Int 95:12-18, 2005

5) Masumori N, Tsukamoto T, Kumamoto Y et al:Decline of sexual function with age in Japanese men compared with American men-results of two community-based studies. Urology 54:335-344, 1999

6) 熊本悦明:男はいつまで男たりうるか-中高年男性の性を考える-. Geriatric Medicine 43:269-293, 2005

7) 熊本悦明, 山口康宏, 佐藤嘉一ほか:Anti-androgenの性機能におよぼす影響:アリルエストレノールおよびクロルマジノンの二重盲検法比較試験第I報夜間睡眠時勃起現象 (NPT) 測定による検討. 泌尿紀要 36:213-226, 1990

8) Noguchi K, Suzuki K, Teranishi J et al:Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. Hinyokika Kiyo 52:527-530, 2006

9) 齊藤泰:前立腺肥大症に対するホルモン療法のコツ. 臨床泌尿器科のコツと落とし穴1検査・診断法, 薬物療法 (阿曽佳郎編). 東京, 中山書店, 1999, pp.152-153

P.227 掲載の参考文献

1) Schulman CC, Lock TM, Buzelin JM et al:Long-term use of tamsulosin to treat Iower urinary tract symptoms/benign prostatic hyperplasia. J Urol 166:1358-1363, 2001

2) Narayan P, Evans CP, Moon T:Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 170 (2 Pt 1):498-502, 2003

3) Rigatti P, Brausi M, Scarpa RM et al:A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 6:315-323, 2003

4) Ichioka K, Ohara H, Terada NT et al:Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia. Int J Urol 870-875, 2004

5) 河邊香月, 吉田正貴, 荒川創一, 竹内秀雄:シロドシン臨床試験グループ:新規α1A選択的アドレナリン受容体遮断薬シロドシンの前立腺肥大症に伴う下部尿路機能障害に対する長期投与時の評価-第III相長期投与試験-. 泌尿器外科 19:153-164, 2006

6) Kawabe K, Yoshida M, Homma Y:Silodosin Clinical Study Group:Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia:results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98:1019-1024, 2006

P.233 掲載の参考文献

1) 大園誠一郎, 雄谷剛士, 夏目修ほか:経済的効率を加味した前立腺肥大症に対する各種治療法の検討. 泌尿器外科 14:900-902, 2001

2) Debruyne FM, Witjes WP, Fitzpatrick J et al:The international terazosin trial:a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. Eur Urol 30:369-376, 1996

3) Okada H, Kawaida N, Ogawa T et al:Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group. Scand J Urol Nephrol 30:379-385, 1996

4) Kaplan SA, Reis RB, Cologna A et al:Intermittent α-blocker therapy in the treatment of men with lower urinary tract symptoms. Urology 52:12-16, 1998

5) 小林実, 徳江章彦:OP2-057 下部尿路症状に対するα1-blocker投与中止後の下部尿路症状の変化について. 日泌尿会誌 95:365, 2004

6) 横山光彦, 井上雅, 西山康弘, 公文裕巳:前立腺肥大症に伴う下部尿路症状に対するα1遮断薬休薬の可能性についての検討. 日泌尿会誌 96:328, 2005

7) 小倉啓司, 福井勝一, 長船崇:APP-076α-ブロッカーが有効であった下部尿路症状を有する男性に対する投薬中止の試み. 日泌尿会誌 97:260, 2006

8) Hong SJ, Ko WJ, Kim SI, Chung BH:Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia:an observational cohort study. Eur Urol 44:94-100, 2003

9) de la Rosette JJ, Kortmann BB, Rossi C et al:Long-term risk of retreatment of patients using α-blockers for lower urinary tract symptoms. J Urol 167:1734-1739, 2002

10) 古屋亮兒, 竹山康, 田口圭介ほか:前立腺肥大症に対する塩酸タムスロシン長期投与後の臨床経過に関する検討. 泌尿器外科 14:1369-1372, 2001

11) McConnell JD:The long term effects of medical therapy on the progression of BPH:results from the MTOPS trial. J Urol 167:265, 2002

12) Barkin J, Guimaraes M, Jacobi G et al:α-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol 44:461-466, 2003

P.243 掲載の参考文献

1) Machino R, Kakizaki H, Ameda K et al:Detrusor instability with equivocal obstruction:A predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn 21:444-449, 2002

2) Mitterberger M, Pallwein L, Gradl J et al:Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int 99:831-835, 2007

3) Madersbacher S, Klingler HC, Schatzl G et al:Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol 156:1662-1667, 1996

4) Palacio A, Hernandez C, Marques A et al:Long term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL syudy):first-year follow-up report. Arch Esp Urol 57:451-460, 2004

5) Takahashi S, Tajima A, Matsushima H et al:Clinical efficacy of an α1A/D adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol 13:15-20, 2006

6) Ohtake A, Ukai M, Saitoh C et al:Effect of tamsulosin on spontaneous bladder contraction in conscious rats with bladder outlet obstruction:comparison with effect on intraurethral pressure. Eur J Pharmacol 545:185-191, 2006

7) Tatemichi S, Akiyama K, Kobayashi M et al:Aselective α1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 176:1236-1241, 2006

8) Abrams P, Kaplan S, De Koning Gans HJ, Millard R:Safety and tolerabilitv of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175:999-1004, 2006

9) Novara G, Galfano A, Ficarra V, Artibani W:Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms:A systematic review. Eur Urol 50:675-683, 2006

10) Kaplan SA, Roehrborn CG, Rovner ES et al:Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder:a randomized controlled trial. JAMA 296:2319-2328, 2006

11) Lee JY, Kim HW, Lee SJ et al:Comparison of doxisazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817-820, 2004

P.252 掲載の参考文献

1) 泌尿器科領域の治療標準化に関する研究班編:EBMに基づく前立腺肥大症診療ガイドライン. じほう, 東京, 2001

2) 大園誠一郎, 藤本清秀, 平山暁秀:前立腺肥大症の診療ガイドライン:その実践と検証. Urology View 1:36-43, 2003

3) 排尿障害臨床試験ガイドライン作成委員会編:排尿障害臨床試験ガイドライン. 医学図書出版, 東京, 1997

4) 大園誠一郎, 雄谷剛士, 藤本清秀ほか:BPH治療の経済的効率の検討-α1ブロッカー (塩酸タムスロシン) とTURPの比較-. 臨牀と研究 83:949-953, 2006

5) 日本排尿機能学会過活動膀胱ガイドライン作成委員会編:過活動膀胱診療ガイドライン. ブラックウェルパブリッシング, 東京, 2005

P.257 掲載の参考文献

1) 日本排尿機能学会過活動膀胱診療ガイドライン作成委員会編:過活動膀胱診療ガイドライン. ブラックウェルパブリッシング, 東京, 2005

2) 日本間質性膀胱炎研究会ガイドライン作成委員会編:間質性膀胱炎診療ガイドライン. ブラックウェルパブリッシング, 東京, 2007

P.270 掲載の参考文献

1) Watanabe H, Kawauchi A, Kitamori T, Azuma Y:Treatment system for nocturnal enuresis according to an original classification system. Eur Urol 25:43-50, 1994

2) Yeung CK, Sreedhar B, Sihoe JD et al:Differences in characteristics of nocturnal enuresis between children and adolescents:a critical appraisal from a large epidemiological study. BJU Int 97:1069-1073, 2006

3) Neveus T, von Gontard A, Hoebeke P et al:The standardization of terminology of lower urinary tract function in children and adolescents:report from the Standardisation Committee of the International Children's Continence Society. J Urol 176:314-324, 2006

4) McKenna PH, Herndon CD, Connery S, Ferrer FA:Pelvic floor muscle retraining for pediatric voiding dysfunction using interactive computer games. J Urol 162:1056-1063, 1999

5) Koff SA, Wagner TT, Jayanthi VR:The relationship among dysfunctional elimination syndrome, primary vesicoureteral reflux and urinary tract infections in children. J Urol 160:1019-1022, 1998

P.279 掲載の参考文献

1) 菅谷公男, 西島さおり:夜間頻尿の成因と治療. 臨床泌尿器科 58:103-111, 2004

2) 菅谷公男, 西島さおり, 宮里実, 小川由英:夜間頻尿の病態診断. EBMジャーナル 7 592-597, 2006

P.286 掲載の参考文献

1) 鈴木俊明, 勝岡洋治:排尿日誌. 泌尿器外科 19:11-16, 2006

2) 石橋寿子:排尿日誌のつけ方・読み方のコツ. 臨牀看護 33:186-192, 2007

3) Amundsen CL, Parsons M, Tissot B et al:Bladder diary measurements in asymptomatic females:functional bladder capacity, frequency, and 24-hr volume. Neurourol Urodyn 26:341-349, 2007

4) Parsons M, Tissot W, Cardozo L et al:Normative bladder diary measurements:night versus day. Neurourol Urodyn 26:465-473, 2007

5) 本間之夫, 西沢理, 山口脩:下部尿路機能に関する用語基準:国際禁制学会標準化部会報告. 日本排尿機能学会誌 14:278-289, 2003

6) 嘉村康邦:排尿記録 (Frequency-Volume Chart) が教えてくれるもの. 夜尿症研究 8:27-33, 2003

7) Wyman JF, Choi SC, Harkins SW et al:The urinary diary in evaluation of incontinent women:atest-retest analysis. Obstet Gynecol 71:712-817, 1988

8) Schick E, Jolivet-Tremblay M, Dupont C et al:Frequency-volume chart:the minimum number of days required to obtain reliable results. Neurourol Urodyn 22:92-96, 2003

9) 日本泌尿器科学会日本Endourology・ESWL学会日本尿路結石症学会編:尿路結石症診療ガイドライン. 金原出版, 東京, 2003

10) Wein AJ, Khullar V, Wang JT, Guan Z:Achieving continence with antimuscarinic therapy for overactive bladder:effects of baseline incontinence severity and bladder diary duration. BJU Int 99:360-363, 2007

P.293 掲載の参考文献

1) 日本排尿機能学会過活動膀胱ガイドライン作成委員会編:過活動膀胱診療ガイドライン. ブラックウェルパブリッシング, 東京, 2005

2) 本間之夫, 吉田正貴, 小原健司ほか:過活動膀胱症状質問票 (overactive bladder symptom score:OABSS) の開発と妥当性の検討. 日泌尿会誌 96:182, 2005

3) 本間之夫, 柿崎秀宏, 後藤百万ほか:排尿に関する疫学的研究委員会. 排尿に関する疫学的研究. 日排尿機能会誌 14:266-277, 2003

4) 本間之夫, 松井研一, 山口脩:過活動膀胱の症状の下限基準. 日排尿機能会誌 15:109, 2004

5) 泌尿器科領域の治療標準化に関する研究班編:EBMに基づく前立腺肥大症診療ガイドライン. じほう, 東京, 2001

6) Kaplan SA, Olsson CA, Te AE:The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms:at 2 years of followup, does it work? J Urol 155:1971-1974, 1996

7) Koyanagi T, Artibani W, Correa R et al:Initial diagnostic evaluation of men with lower urinary tract symptoms. Proceedings of 4th international consultation on benign prostatic hyperplasia (BPH) (Denis L et al eds.). Health Publication, Plymouth, 1998, pp.179-264

8) 排尿障害臨床試験ガイドライン作成委員会編:排尿障害臨床試験ガイドライン. 医学図書出版, 東京, 1997

9) 本間之夫, 塚本泰司, 安田耕作ほか:International Prostate Symptom ScoreとBPH Impact Indexの日本語訳の言語的妥当性に関する研究. 日泌尿会誌 93:669-680, 2002

Chapter 6 ガイドライン

P.312 掲載の参考文献

1) 長谷川友紀:根拠に基づいた診療ガイドラインとは. Urology View vol.1 No.6:8-16, 2003

2) 泌尿器科領域の治療標準化に関する研究班編:EBMに基づく前立腺肥大症診療ガイドライン. じほう, 東京, 2001

3) 日本排尿機能学会過活動膀胱ガイドライン作成委員会編:過活動膀胱診療ガイドライン. ブラックウェルパブリッシング, 東京, 2005

4) 治療法の一覧:間質性膀胱炎診療ガイドライン (日本間質性膀胱炎研究会ガイドライン作成委員会編). ブラックウェルパブリッシング, 東京, 2007, pp.64-65

5) Berry SJ, Coffey DS, Walsh PC, Ewing LL:The development of human benign prostatic hyperplasia with age. J Urol 132:474-479, 1984

6) Black L, Naslund MJ, Gilbert TD Jr et al:An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 12:S99-S110, 2006

7) Hansen BJ, Meyhoff HH, Nordling J et al:Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. Scand J Urol Nephrol 30:373-377, 1996

8) Kuntz RM:Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol 49:961-969, 2006

9) Malek RS, Kuntzman RS, Barrett DM:Photoselective potassiumtitanyl-phosphate laser vaporization of the benign obstructive prostate:observations on long-term outcomes. J Urol 174:1344-1348, 2005

10) Athanasopoulos A, Gyftopoulos K, Giannitsas K et al:Combinationtreatment with an α-blocker plus an anticholinergic for bladder outlet obstruction:aprospective, randomized, controlled study. J Urol 169:2253-2256, 2003

11) Lee JY, Kim HW, Lee SJ et al:Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94:817-820, 2004

12) 本間之夫, 柿崎秀宏, 後藤百万ほか:排尿に関する疫学的研究. 日排尿機能会誌 14:266-277, 2003

13) Dowd TT, Campbell JM, Jones JA:Fluid intake and urinaryincontinence in older community-dwelling women. J Commttnity Health Nurs 13:179-186, 1996

14) Bryant CM, Dowell CJ, Fairbrother G:A randomized trial of the effects of caffeine upon frequency, urgency and urge incontinence. Neurourol Urodyn 19:501-502, 2000

15) Nygaard IE, Kreder KJ, Lepic MM et al:Efficacy of pelvic floor muscle exercises in woman with stress, urge and mixed urinaryincontinence. Am J Obstet Gynecol 174:120-125, 1996

16) Burgio KL, Locher JL, Goode PS:Combined behavioral and drug therapy for Urge incontinence in older women. J Am Geriatr Soc 48:370-374, 2000

17) Colling J, Ouslander J, Hadley BJ et al:The effects of patterned urge-response toileting (PURT) on urinary incontinence among nursing home residents. J Am Geriatr Soc 40:135-141, 1992

18) 関成人:過活動膀胱. Urology View 5:96-101, 2007

19) Schulte-Baukloh H, Weiss C, Stolze T et al:Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity:urodynamlc outcome and patient satisfaction. Urology 66:82-87, 2005

書評

書評を投稿する

最近チェックした商品履歴

Loading...